March 26, 2017 1:24 AM ET

Pharmaceuticals

Company Overview of Novartis Pharma AG

Company Overview

Novartis Pharma AG provides treatments for Alzheimer’s disease, Parkinson’s disease, Attention-Deficit/Hyperactivity Disorder, epilepsy, schizophrenia, and migraine. It is also developing a treatment for type 2 diabetes; drugs therapies that improve insulin action to increase glucose disposal in the muscle, to limit its production in the liver, and to improve the kinetics of insulin secretion; and oral and physiological approach to enhancing glucagon like peptide-1 activity, which acts to stimulate insulin secretion and inhibit glucagon production. The company is based in Basel, Switzerland. Novartis Pharma AG operates as a subsidiary of Novartis AG.

Forum 1

Novartis Campus

Basel,  4056

Switzerland

Phone:

41 61 324 11 11

Fax:

41 61 324 80 01

Key Executives for Novartis Pharma AG

President of HBA Europe and Head of New Marketing Initiatives
Compensation as of Fiscal Year 2016.

Novartis Pharma AG Key Developments

Novartis Pharma AG Presents at Sachs Associates 10th Annual European Life Sciences CEO Forum & Exhibition, Mar-06-2017 04:15 PM

Novartis Pharma AG Presents at Sachs Associates 10th Annual European Life Sciences CEO Forum & Exhibition, Mar-06-2017 04:15 PM. Venue: Hilton Zurich Airport Hotel, Hohenbuehlstrasse 10, Opfikon-Glattbrugg 8152 Zurich, Switzerland. Speakers: Markus Kalousek, Global BD&L S&E Franchise Head (I&D).

Novartis Pharma AG Presents at 9th Annual European Life Sciences CEO Forum & Exhibition, Mar-15-2016 through Mar-16-2016

Novartis Pharma AG Presents at 9th Annual European Life Sciences CEO Forum & Exhibition, Mar-15-2016 through Mar-16-2016. Venue: Hilton Zurich Airport Hotel, 27 Belsize Lane, London | NW3 5AS, United Kingdom. Presentation Date & Speakers: Mar-15-2016, Charles Bailey, Head of Search & Evaluation, Neurosciences, Markus Kalousek, Global BD&L S&E Franchise Head (I&D), Ulrich Muehlner, Global Head Outcomes Technologies Incubator (NOVAE).

Novartis Pharma AG Presents at BIO-Europe 2015, Nov-02-2015 through Nov-04-2015

Novartis Pharma AG Presents at BIO-Europe 2015, Nov-02-2015 through Nov-04-2015. Venue: Munich, Germany. Presentation Date & Speakers: Nov-02-2015, Corinne Savill, Head, Pharma Business Development & Licensing.

Similar Private Companies By Industry

Company Name Region
Acino International AG Europe
Activen SA Europe
AL-S Pharma AG Europe
Albea Pharmaceuticals AG Europe
Alpen Pharma AG Europe

Recent Private Companies Transactions

Type
Date
Target
Private Placement
December 19, 2016
Conatus Pharmaceuticals Inc.
Private Placement
September 23, 2016
BioLine Rx Ltd
Merger/Acquisition
May 24, 2016
Novartis AG,Worldwide Rights to manufacture Tekturna, Tekturna HCT, Rasilez and Rasilez HCT
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Novartis Pharma AG, please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.